Idiopathic Slow Transit Constipation: Pathophysiology, Diagnosis, and Management.
Luke J Vlismas, William Wu, Vincent Ho
https://pubmed.ncbi.nlm.nih.gov/38256369/Actively Recruiting
Led by Third Military Medical University · Updated on 2026-08-05
346
Participants Needed
20
Research Sites
4 weeks
Total Duration
Slow-transit constipation STC is a subtype of chronic constipation characterized by rare bowel movements, straining, and abdominal discomfort, often worsening over time and reducing quality of life. While lubiprostone has proven effective for other constipation types, evidence for its use in STC is limited. This trial evaluates lubiprostones safety and effectiveness specifically for people with STC to improve treatment options. Participants will receive either lubiprostone capsules taken orally twice daily at a dose of 24 micrograms with meals or polyethylene glycol PEG, a common laxative, taken as a dissolved powder twice daily. Both treatments last for 4 weeks. Medication use and adherence will be tracked through diaries and pill counts. This trial is randomized and compares the effects of these two treatments on bowel habits. During the study, participants will keep diaries recording bowel movements and complete questionnaires about symptoms and quality of life. Researchers will monitor changes in spontaneous bowel movements, stool form, straining, and patient satisfaction over 4 weeks. Safety is also assessed by tracking adverse reactions like nausea or abdominal pain. Overall participation lasts about 6 weeks including screening and follow-up assessments.
CONDITIONS
Efficacy and Safety of Lubiprostone in the Treatment of Slow Transit Constipation
Y
yansen Huang, MS
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Third Military Medical University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 4 weeks
Participants receive either lubiprostone capsules twice daily or polyethylene glycol powder twice daily for 4 weeks. Medication use and adherence are monitored.
Regular visits for monitoring and assessments
Duration - Up to 4 weeks after treatment initiation
Participants complete symptom diaries and questionnaires to assess bowel movements, stool form, straining, quality of life, and safety for up to 4 weeks after treatment begins.
Periodic visits or contacts for safety and symptom assessment
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Luke J Vlismas, William Wu, Vincent Ho
https://pubmed.ncbi.nlm.nih.gov/38256369/Lin Chang, William D Chey, Aamer Imdad...
https://pubmed.ncbi.nlm.nih.gov/37211380/R Cinca, D Chera, H-J Gruss...
https://pubmed.ncbi.nlm.nih.gov/23480216/Heather Lee-Robichaud, Kathryn Thomas, Jenna Morgan...
https://pubmed.ncbi.nlm.nih.gov/20614462/Byron Cryer, Seymour Katz, Ricardo Vallejo...
https://pubmed.ncbi.nlm.nih.gov/24716835/Fan Li, Tao Fu, Wei-Dong Tong...
https://pubmed.ncbi.nlm.nih.gov/27046523/Michael D Crowell
https://pubmed.ncbi.nlm.nih.gov/19404263/Jennifer Christie, Sagar Shroff, Nikrad Shahnavaz...
https://pubmed.ncbi.nlm.nih.gov/27922028/Natalie J Carter, Lesley J Scott
https://pubmed.ncbi.nlm.nih.gov/19537839/Shin Fukudo, Michio Hongo, Hiroshi Kaneko...
https://pubmed.ncbi.nlm.nih.gov/25158925/Third Military Medical University
Lead Sponsor